Ixmyelocel-T
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dilated Cardiomyopathy
Conditions
Dilated Cardiomyopathy
Trial Timeline
Dec 1, 2009 → Dec 5, 2013
NCT ID
NCT01020968About Ixmyelocel-T
Ixmyelocel-T is a phase 2 stage product being developed by Vericel for Dilated Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01020968. Target conditions include Dilated Cardiomyopathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01670981 | Phase 2 | Completed |
| NCT01483898 | Phase 3 | Completed |
| NCT01020968 | Phase 2 | Completed |
| NCT00765518 | Phase 2 | Completed |
| NCT00505219 | Phase 3 | Completed |
Competing Products
10 competing products in Dilated Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 85 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 33 |
| AZD4063 | AstraZeneca | Phase 1 | 33 |
| ARRY-371797, p38 inhibitor, oral | Pfizer | Phase 2 | 51 |
| ARRY-371797 (PF-07265803) | Pfizer | Phase 3 | 76 |
| ARRY-371797, p38 inhibitor; oral | Pfizer | Phase 2 | 51 |
| danicamtiv | Bristol Myers Squibb | Phase 2 | 51 |
| ixmyelocel-T | Vericel | Phase 2 | 47 |
| Ixmyelocel-T | Vericel | Phase 2 | 47 |
| talfirastide | Constant Therapeutics | Phase 2 | 44 |